Search
dalcetrapib (JTT-705)
Mechanism of action:
- inhibits cholesterol ester transfer protein (CETP)
- increases HDL cholesterol
Clinical trials:
[1]
- study characteristics
- 15,871 patients with recent acute coronary syndrome
- mean age, 60; about 80% men
- median follow-up of 31 months
- trial was stopped for futility
- primary endpoint: death from cardiovascular event
- treatment:
- randomized to dalcetrapib or placebo between 4 & 12 weeks after the index event
- results:
- dalcetrapib markedly increased in HDL cholesterol
- no significant effect on the primary endpoint (or any of its components) compared with placebo
Interactions
drug adverse effects of anti-hyperlipidemic agents
Related
cholesteryl ester transfer protein; lipid transfer protein I (CETP)
General
cholesteryl ester transfer protein (CETP) inhibitor
amide
thiol ester
Database Correlations
PUBCHEM correlations
References
- Schwartz GG et al.
Effects of dalcetrapib in patients with a recent acute coronary
syndrome.
N Engl J Med 2012 Nov 5
PMID: 23126252
http://www.nejm.org/doi/full/10.1056/NEJMoa1206797